Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06136572
Recruiting Not applicable

Epidemiology of Assertiveness and Emotion Management Disorders in People With Tourette's Syndrome

NCT06136572 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Clermont-Ferrand
Phase
Not applicable
Started
2024-05-06
Last updated
2026-02-27

Condition(s) studied

Tourette Syndrome

Investigational drug(s) / intervention(s)

Rathus Assertiveness scale

Rathus Assertiveness scale: Questionnaire completion

Study summary

The goal of this study is to evaluate the proportion of assertiveness difficulties in Tourette syndrome. Participants will complete several e-questionnaires (on assertiveness, Tourette severity, quality of life, self-esteem and comorbidities like depression, anxiety...).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Tourette syndrome * Participants aged 18 years or over Exclusion Criteria: * Participants under legal protection * Inability to complete questionnaires alone

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CHU Clermont-Ferrand Clermont-Ferrand France Recruiting

More University Hospital, Clermont-Ferrand trials in France

Importance of the Type of Communication Used During Paraapical Anesthesia in Dentistry Recruiting
Optimization of a Non-invasive Electrophysiological Method for Studying the Functionality of Auditory Nerve Fibers Recruiting
Exploration of High Frequency Otoacoustic Emissions and Developmental Language Disorders Starting soon
QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up Recruiting
Comparison of the Immediate Effect of Passive vs. Passive-Active Hamstring Stretching on Flexibility in Patients With Chronic Low Back Pain Recruiting

Other trials for the same condition

Multimodal Electrophysiological Study of Cortico-subcortical Biomarkers of Tics in Tourette Syndrome Recruiting
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome Active, not recruiting
Observational Database on Deep Brain Stimulation in Tourette Syndrome Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06136572 on ClinicalTrials.gov ↗ ← All trials in France